Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency
Nobel House, 17 Smith Square
London
SW1P 3JR
UK
Contact person: Simeon Hadebe
E-mail: dhsc.covidmeds@dhsc.gov.uk
NUTS: UKI32
Internet address(es)
Main address: https://www.gov.uk/government/organisations/uk-health-security-agency
Address of the buyer profile: https://www.gov.uk/government/organisations/uk-health-security-agency
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Supportive Medicines Phase 5a - Propofol 1g/50ml Emulsion for Infusion
Reference number: CM-EMI-21-C57450
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
A requirement for the supply of 375,000 vials of Propofol 1g / 50 ml emulsion for infusion (for use in Intensive Treatment Units) in preparation for further waves of Covid 19 in Winter 2021/Spring 2022.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
1.00
GBP
II.2) Description
II.2.3) Place of performance
NUTS code:
UK
Main site or place of performance:
Haydock, England
II.2.4) Description of the procurement
The Department of Health and Social Care (DHSC) has awarded a contract for the supply of 375,000 vials of Propofol 1g / 50 ml emulsion for infusion (for use in Intensive Treatment Units) in preparation for further waves of Covid 19 in Winter 2021/Spring 2022. The contract was awarded on behalf of United Kingdom Health Security Agency (UKHSA)
II.2.5) Award criteria
Quality criterion: Availability
/ Weighting: 100
Price
/ Weighting:
0
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Award of a contract without prior publication of a call for competition
Justification for selected award procedure:
Extreme urgency brought about by events unforeseeable for the contracting authority and in accordance with the strict conditions stated in the Directive
Explanation
The Coronavirus disease (Covid-19) is a serious infectious respiratory disease and its consequences pose a risk to life. The Covid-19 pandemic supportive medicines stockpile was designed as a ‘one off’ build to target volumes of a defined range of critical products used within the intensive treatment units and end of life environments. However, developments in Winter 2021 around the Omicron variant and heightened risk perception within Government prompted activation of the ‘Challenging Winter Peak’ Scenario at very short notice, resulting in an urgent requirement to procure additional volumes of some critical products to avoid their complete stockout in the month of January 2022. The global stock of Propofol is limited and there are many buyers competing for the same supplies. It is imperative that security of supply is maintained for public health purposes. Due to the short delivery timeframe required to mitigate a complete stockout, the authority did not have sufficient time to comply with the standard open procedure time scales for this procurement. Accordingly, the Authority used the negotiated procedure without prior publication – Regulation 32(2)(c) – Extreme Urgency Route (i.e. direct award) permitted under the Public Contract Regulations 2015 (as amended) to conduct this procurement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
23/01/2022
V.2.2) Information about tenders
Number of tenders received: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
B. Braun Medical Limited
2296559
Thorncliffe Park, Sheffield
Sheffield
S35 2PW
UK
NUTS: UKE32
Internet address(es)
URL: http://www.bbraun.co.uk
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 1.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per vial. This will (i) commercially prejudice the contracting authority in its commercial dealings with other suppliers; and (ii) impact fair competition between suppliers.<br/><br/>The Contract is for the benefit of the Authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of Products to NHS bodies, local authorities, other government departments and their executive agencies or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting Products delivered against the contract may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories .
VI.4) Procedures for review
VI.4.1) Review body
The High Court
Strand
London
WC2A 2LL
UK
E-mail: generaloffice@administrativecourtoffice.justice.gov.uk
Internet address(es)
URL: https://www.gov.uk/courts-tribunals
VI.5) Date of dispatch of this notice
17/02/2022